Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

Using patient-derived B cells, Kling-Select facilitates the rapid detection of new antibodies and preserved viral epitopes.

Dutch privately-held biotech Kling Bio today announced it has entered into a collaboration and license option agreement with French pharma major Sanofi for the discovery of antibodies and epitopes ...

Kling Bio has announced a new collaboration and licence option agreement with Sanofi to accelerate the discovery of neutralising antibodies using its proprietary B cell platform, Kling-Select.

Debbie Kling to step down after eights years of growth, opportunity and challenges as Nampa mayor. Her successor could face issues over growth, funding ...

After leading Nampa for nearly eight years, Mayor Debbie Kling announced Monday that she will not be seeking a third term in the upcoming 2025 election.

After leading Nampa for nearly eight years, Mayor Debbie Kling announced Monday that she will not be seeking a third term in the upcoming 2025 election.

Metro Transit's slow but popular Route 21 bus route is coming to an end after 70 years, though not without a final toast goodbye.

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

Sanofi SAN0.99%increase; green up pointing triangle agreed to buy Blueprint Medicines BPMC 0.12%increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.